Stockscreener 앱 받기
74.20
3.33%
2.39
시간 외 거래:
74.25
0.05
+0.07%
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
Can trapped investors hope for a rebound in Mirum Pharmaceuticals Inc.Weekly Market Outlook & Daily Price Action Insights - Newser
Why Mirum Pharmaceuticals Inc. stock attracts strong analyst attention2025 Big Picture & Long-Term Growth Stock Strategies - Newser
How hedge fund analytics apply to Mirum Pharmaceuticals Inc. stockJuly 2025 Catalysts & Weekly Setup with ROI Potential - Newser
What to do if you’re stuck in Mirum Pharmaceuticals Inc.July 2025 Decliners & Fast Exit Strategy with Risk Control - Newser
Mirum Pharmaceuticals stock hits all-time high at 67.5 USD - Investing.com
Volume Profile Shows Strong Base for Mirum Pharmaceuticals Inc.Weekly Investment Report & Consistent Profit Focused Trading Strategies - beatles.ru
Mirum Pharmaceuticals Inc. Moves Into Overbought Range Analysts Cautious2025 Geopolitical Influence & Free AI Powered Buy and Sell Recommendations - newsyoung.net
Mirum Pharmaceuticals’ SWOT analysis: rare disease biotech stock shows promise - Investing.com
Mirum Pharmaceuticals CFO Sells $526,960 Worth of Stock Amid Q2 Growth and Raised Price Targets - AInvest
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates - MSN
Mirum Pharmaceuticals Insider Sold Shares Worth $2,480,000, According to a Recent SEC Filing - MarketScreener
Mirum Pharmaceuticals (NASDAQ:MIRM) PT Set at $89.00 by Stifel Nicolaus - Defense World
Mirum Pharma CEO Peetz sells $2.48 million in shares By Investing.com - Investing.com Canada
Mirum Pharma CFO Eric Bjerkholt sells $524k in stock By Investing.com - Investing.com Canada
What earnings revisions data tells us about Mirum Pharmaceuticals Inc.Forecasting Stock Moves with AI Insights - Newser
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $89.00 at Evercore ISI - MarketBeat
Mirum Pharmaceuticals Inc. Breaks Losing Streak — Is the Trend ReversingReal Trader Watchlist of Hot Stocks Released - 선데이타임즈
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Up 9.1% on Analyst Upgrade - Defense World
Is Mirum Pharmaceuticals Inc. forming bullish engulfing patternsBest 5x Return Trade Entries - thegnnews.com
Mirum Pharmaceuticals Inc. stock momentum explainedTrade Safety Report with Pattern Insights - Newser
Stifel Initiates Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Announces Target Price $89 - 富途牛牛
Mirum's Meteoric Surge: What's Fueling the 9.38% Intraday Rally? - AInvest
HC Wainwright Issues Positive Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price - MarketBeat
Mirum’s Financial Rocket: Soaring Figures, Intriguing Questions - StocksToTrade
Mirum Soars 10% on Analyst Upgrades and Pipeline Catalysts: Is This the Start of a Biotech Breakout? - AInvest
Analysts Just Shipped A Substantial Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates - simplywall.st
Mirum Pharmaceuticals: Q2 Results Continues To Show Positive Momentum (NASDAQ:MIRM) - Seeking Alpha
Stifel resumes Mirum Pharmaceuticals stock coverage with Buy rating By Investing.com - Investing.com Canada
Cantor Fitzgerald Brokers Boost Earnings Estimates for MIRM - Defense World
Leerink Partnrs Has Bullish Forecast for MIRM Q3 Earnings - Defense World
HC Wainwright Issues Positive Estimate for MIRM Earnings - Defense World
Mirum Pharmaceuticals Delivers Growth With Orphan Liver Drug Success - Finimize
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $80.00 - Defense World
Evercore ISI Raises Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $89.00 - Defense World
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - MSN
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q2 2025 Earnings Call Transcript - MSN
Insider Selling at Mirum Pharmaceuticals: A Signal of Confidence or Caution for Long-Term Investors? - AInvest
A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $66 to $89 - 富途牛牛
BioLife Solutions: HC Wainwright Raises PT to $32, Maintains Buy Rating - AInvest
Zurcher Kantonalbank Zurich Cantonalbank Buys 398 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 12-Month High After Earnings Beat - Defense World
Mirum Pharmaceuticals price target raised to $82 from $77 at Raymond James - TipRanks
Mirum Pharmaceuticals Reports Strong Q2 Growth and Raises Guidance - TipRanks
Mirum Pharmaceuticals Raises Revenue Guidance, Secures Reimbursement in Japan, and Expands Product Portfolio - AInvest
Citizens JMP Raises Mirum Pharmaceuticals Price Target to $81, Maintains Outperform Rating - AInvest
MIRM Stock Flying High: Too Late to Buy? - StocksToTrade
Mirum Pharmaceuticals shares rise 12.83% intraday after reporting strong Q2 results and raising 2025 guidance. - AInvest
MIRM Stock Up On Q2 Earnings And Revenue Beat, Raised 2025 View - Barchart.com
Mirum Pharmaceuticals price target raised to $81 from $79 at Citizens JMP - TipRanks
Mirum Pharmaceuticals stock hits all-time high at 55.25 USD By Investing.com - Investing.com Canada
Mirum Soars 10.5% on Earnings Beat and Revenue Surge: A Biotech Breakout in the Making? - AInvest
Mirum Pharmaceuticals stock hits all-time high at 55.25 USD - Investing.com
Mirum: JMP Securities Raises PT to $81, Maintains Market Outperform - AInvest
Mirum:Raymond James raises PT to $82, maintains Strong Buy rating. - AInvest
Mirum Pharmaceuticals stock price target raised to $80 from $73 at H.C. Wainwright - Investing.com Canada
Mirum Pharmaceuticals price target raised to $80 from $73 at H.C. Wainwright - TipRanks
Mirum:HC Wainwright Raises PT to $80, Maintains Buy Rating - AInvest
Mirum Pharmaceuticals stock price target raised to $81 by JMP - Investing.com South Africa
0.95%
0.90%
자본화:
|
볼륨(24시간):